纳武利尤单抗治疗胃癌患者的免疫相关不良事件的预后影响。
Prognostic Impact of Immune-related Adverse Events in Gastric Cancer Patients Treated With Nivolumab.
机构信息
Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Kanagawa, Japan.
Department of Surgery, Yokohama City University, Kanagawa, Japan.
出版信息
Anticancer Res. 2022 Mar;42(3):1535-1540. doi: 10.21873/anticanres.15626.
BACKGROUND/AIM: To evaluate the impact of development of nivolumab monotherapy-induced immune-related adverse events (irAEs) and continuing nivolumab with irAEs on the survival of patients with gastric cancer (GC).
PATIENTS AND METHODS
Patients with unresectable advanced GC and recurrence after curative resection who received nivolumab monotherapy were included in the study. Survival was compared between patients who did and did not develop irAEs, and between those who continued and discontinued treatment due to irAEs.
RESULTS
Of 110 GC patients, 22 developed irAEs. Grade ≥3 IrAEs included rash and diarrhoea associated with enteritis. Progression-free and overall survival (OS) were significantly better in patients with irAEs than in those without. The overall survival of patients who continued treatment despite irAEs was better than that of those who discontinued treatment.
CONCLUSION
irAE development was associated with better survival in patients with GC who received nivolumab monotherapy. Continuing nivolumab with appropriate treatment in GC patients with irAEs may improve survival.
背景/目的：评估纳武利尤单抗单药治疗引起的免疫相关不良反应 (irAE) 的发展以及继续使用纳武利尤单抗联合 irAE 对胃癌 (GC) 患者生存的影响。
患者和方法
本研究纳入了接受纳武利尤单抗单药治疗的不可切除的晚期 GC 患者和根治性切除后复发的患者。比较了发生和未发生 irAE 的患者以及因 irAE 继续和停止治疗的患者的生存情况。
结果
在 110 例 GC 患者中，有 22 例发生 irAE。≥3 级 irAE 包括皮疹和与肠炎相关的腹泻。发生 irAE 的患者无进展生存期和总生存期 (OS) 明显优于未发生 irAE 的患者。尽管存在 irAE，但继续治疗的患者的总生存期优于停止治疗的患者。
结论
irAE 的发生与接受纳武利尤单抗单药治疗的 GC 患者的生存改善相关。在 irAE 的 GC 患者中继续使用纳武利尤单抗联合适当的治疗可能会改善生存。
Zotero 插件